🏛️ Verified NIH Record • Updated 2026-04-14

Safety and Efficacy of Mesenchymal Stem Cells Associated With Chronic Pancreatitis Pain (NCT06205342)

STEMCAP-1: Safety and Efficacy of Mesenchymal Stem Cells Associated With Chronic Pancreatitis Pain

🟢 Recruiting Early Phase1 💊 Investigational Drug / Biologic Sponsor: Medical University of South Carolina

🩺 Plain-English Summary (8th-Grade Level)

This protocol aims to test whether an infusion of allogeneic bone marrow-derived mesenchymal stromal cells (BM-MSCs) can reduce pain associated with chronic pancreatitis (CP) and explore potential mechanisms of MSC action.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (19 items).

Location: Medical University of South Carolina — Charleston, South Carolina

Age range: 18 Years to 75 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • Acute pancreatitis per 2012 revised Atlanta criteria within the last 30 days.
  • The revised Atlanta classification requires that two or more of the following criteria be met for the diagnosis of acute pancreatitis: (a) abdominal pain suggestive of pancreatitis, (b) serum amylase or lipase level greater than three times the upper normal value, or (c) characteristic imaging findings.
  • Chronic pain syndromes other than pancreatitis that require daily use of opioids in the past 30 days.
  • Severe organ failure(s) likely to interfere with clinical pain outcomes within 6 months.
  • HbA1c \>10%
  • Laboratory values of WBC \<2.0 cells/10\^3, Hemoglobin \<8 gm/dl, and platelets \<100K cells/10\^3, AST or ALT \> 3 times the upper limit of normal, or creatinine \>2.0 mg/dl
  • New York Heart Association Class 2 or higher congestive heart failure
  • Current lung, hematologic, or solid organ malignancy other than skin, or cervical stage 1 cancers within the past 3 years.
  • Subjects with current infection with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection.
  • Active malignancy with the exception of non-melanoma skin cancer.
  • Any subject who has received an investigational drug or device within 30 days before randomization or who is expected to receive an investigational drug or device during this study.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

  • Medical University of South Carolina — Charleston, South Carolina

📞 Contact the Study Coordinator

Phone: (843) 792-2813

Email: bennle@musc.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Chronic Pancreatitis

Explore by condition: All Chronic Pancreatitis clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗